Opendata, web and dolomites

ClearRing SIGNED

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ClearRing project word cloud

Explore the words cloud of the ClearRing project. It provides you a very rough idea of what is the project "ClearRing" about.

hospitals    rapid    gradually    inside    validation    carry    patients    clinical    randomized    symptoms    twice    first    reimbursement    introduce    worldwide    presses    affordable    seek    prostate    procedure    fast    men    bph    position    ce    unmet    trial    complications    age    urethra    benign    patient    risk    operation    diseases    comparatively    solution    safety    life    costly    severity    enlarges    urological    implant    obtain    proarc    authorisation    causing    migration    lifestyles    waiting    undesirable    puts    mark    normal    therapy    drugs    significantly    shaped    safe    invasive    bothersome    60s    function    company    tolerable    clearring    alternative    preservers    reduces    validate    efficient       hyperplasia    treatment    urinary    watchful    encrustation    sexual    70    implantable    minimally    standard    potentially    90    prostatic    revolutionary    surgery    worsening    medical    centres    instead    million    health    resume    quality    blocks    efficacy    200    enlargement    whereas    chance   

Project "ClearRing" data sheet

The following table provides information about the project.

Coordinator
PROARC MEDICAL LTD 

Organization address
address: KIDMA 23
city: PARDES HANA
postcode: 3707923
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙776˙750 €
 EC max contribution 1˙943˙725 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROARC MEDICAL LTD IL (PARDES HANA) coordinator 1˙943˙725.00

Map

 Project objective

Benign Prostatic Hyperplasia (BPH), or prostate enlargement, is one of the most common urological diseases among men. As the prostate enlarges with the age, it presses on and blocks the urethra, causing bothersome urinary symptoms. Over 70% of men in their 60s have symptoms of BPH 1, and 80-90% of men over 80 year old. BPH affects around 200 million men worldwide. The current methods present a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe alternative to drugs and invasive surgery, which carry greater risk of undesirable side effects and complications. ClearRing is a revolutionary treatment of BPH symptoms, based on a pre-shaped implant and a dedicated delivery system. The ClearRing solution is the only minimally invasive system for BPH which is implantable inside the prostate with 0% chance of migration or encrustation. It puts ProArc in a unique position as a first company providing significantly improved health conditions and quality of life. Its rapid procedure enables hospitals to get patients in and out more quickly, creating a better patient experience as well as a more efficient management of medical resources. The minimally invasive procedure reduces the range and severity of side effects allowing patients to resume their normal lifestyles potentially twice as fast as the current standard operation procedure. Furthermore, it preservers sexual function. Overall objective of ProArc is to introduce a BPH treatment which is effective, affordable and with no side-effects, therefore men seek for the treatment instead of watchful waiting for the worsening. Whereas, the key objective of the project is to validate the ClearRing safety and efficacy for BPH treatment through a randomized clinical trial at 3 medical centres. This large scale clinical validation will enable ProArc to obtain the CE mark, and gradually apply for the reimbursement authorisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CLEARRING" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CLEARRING" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More